The estimated Net Worth of Daphne Quimi is at least $7.61 Million dollars as of 17 January 2023. Ms. Quimi owns over 11,923 units of Amicus Therapeutics Inc stock worth over $4,491,456 and over the last 12 years she sold FOLD stock worth over $642,163. In addition, she makes $2,480,750 as Chief Financial Officer at Amicus Therapeutics Inc.
Daphne has made over 22 trades of the Amicus Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she sold 11,923 units of FOLD stock worth $152,495 on 17 January 2023.
The largest trade she's ever made was exercising 30,321 units of Amicus Therapeutics Inc stock on 15 December 2020 worth over $99,150. On average, Daphne trades about 4,230 units every 59 days since 2012. As of 17 January 2023 she still owns at least 398,532 units of Amicus Therapeutics Inc stock.
You can see the complete history of Ms. Quimi stock trades at the bottom of the page.
Daphne E. Quimi CPA serves as Chief Financial Officer of the Company. Previously she served as the Company’s Senior Vice President, Finance and has been employed with Amicus since September 2007. Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at Johnson & Johnson. Ms. Quimi brings extensive experience in public accounting and financial reporting. Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B.A. from the Stern School of Business of New York University. She is a certified public accountant in New Jersey.
As the Chief Financial Officer of Amicus Therapeutics Inc, the total compensation of Daphne Quimi at Amicus Therapeutics Inc is $2,480,750. There are 4 executives at Amicus Therapeutics Inc getting paid more, with John Crowley having the highest compensation of $9,852,660.
Daphne Quimi is 54, she's been the Chief Financial Officer of Amicus Therapeutics Inc since 2019. There are 12 older and 7 younger executives at Amicus Therapeutics Inc. The oldest executive at Amicus Therapeutics Inc is Robert Essner, 72, who is the Independent Director.
Daphne's mailing address filed with the SEC is C/O AMICUS THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA, PA, 19104.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris, and Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: